Context.
We present our findings for the HCN/H
13
CN 1−0 line ratio in the molecular outflow of Arp 220 west based on high-resolution ALMA data.
Aims.
Molecular gas masses in the outflowing gas of ...galaxies driven by active galactic nuclei or starbursts are important parameters for understanding the feedback of these latter two phenomena and star-formation quenching. The conversion factor of line luminosities to masses is related to the optical depth of the molecular lines.
Methods.
Using H
13
CN 1–0, the isotopic line of HCN 1−0, to obtain the line ratio of HCN/H
13
CN 1−0 is an ideal way to derive the optical depth of HCN 1−0 in outflowing gas.
Results.
With the nondetection of H
13
CN 1−0 in the outflowing gas, a 3
σ
lower limit of HCN/H
13
CN 1−0 line ratio is obtained, which is at least three times higher than that found in the whole of the whole system of Arp 220. The high HCN/H
13
CN 1−0 line ratio indicates low opacity of HCN 1−0 in the outflowing gas, even though the upper limit of HCN 1−0 opacity obtained here is still not good enough to draw any robust conclusions if HCN 1−0 is optically thin. A lower conversion factor of HCN 1−0 luminosity to dense gas mass in the outflowing gas should be used than that used for the host galaxy of Arp 220.
Full text
Available for:
FMFMET, NUK, UL, UM, UPUK
Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as second- or further-line treatment. In this open-label, ...randomized, phase 3 CONVINCE trial, we assessed the efficacy and safety of first-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation.
Eligible participants were adults with stage IIIB/IV lung adenocarcinoma and exon 19/21 EGFR mutations. Participants were randomly allocated (1 : 1) to receive oral icotinib or 3-week cycle of cisplatin plus pemetrexed for up to four cycles; non-progressive patients after four cycles were maintained with pemetrexed until disease progression or intolerable toxicity. The primary end point was progression-free survival (PFS) assessed by independent response evaluation committee. Other end points included overall survival (OS) and safety.
Between January 2013 and August 2014, 296 patients were randomized, and 285 patients were treated (148 to icotinib, 137 to chemotherapy). Independent response evaluation committee-assessed PFS was significantly longer in the icotinib group (11.2 versus 7.9 months; hazard ratio, 0.61, 95% confidence interval 0.43-0.87; P = 0.006). No significant difference for OS was observed between treatments in the overall population or in EGFR-mutated subgroups (exon 19 Del/21 L858R). The most common grade 3 or 4 adverse events (AEs) in the icotinib group were rash (14.8%) and diarrhea (7.4%), compared with nausea (45.9%), vomiting (29.2%), and neutropenia (10.9%) in the chemotherapy group. AEs (79.1% versus 94.2%; P < 0.001) and treatment-related AEs (54.1% versus 90.5%; P < 0.001) were significantly fewer in the icotinib group than in the chemotherapy group.
First-line icotinib significantly improves PFS of advanced lung adenocarcinoma patients with EGFR mutation with a tolerable and manageable safety profile. Icotinib should be considered as a first-line treatment for this patient population.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
Summary
Background
Serum vitamin D levels are associated with bone complications in patients with primary biliary cirrhosis (PBC). Increasing evidence suggests a nonskeletal role of vitamin D in ...various autoimmune and liver diseases.
Aim
To investigate the clinical relevance of vitamin D levels in PBC, especially their association with the therapeutic effects of ursodeoxycholic acid (UDCA).
Methods
Consecutive PBC patients were retrospectively reviewed. 25‐hydroxyvitamin D 25(OH)D levels were determined in frozen serum samples collected before initiation of UDCA treatment. Response to UDCA was evaluated by Paris‐I and Barcelona criteria. Logistic regressions were performed to identify the treatment response‐associated parameters.
Results
Among 98 patients, the mean serum 25(OH)D concentration was 17.9 ± 7.6 ng/mL. 25(OH)D levels decreased with increasing histological stage (P = 0.029) and were negatively correlated with bilirubin and alkaline phosphatase levels. After 1 year of UDCA therapy, 31 patients failed to achieve complete response according to Paris‐I criteria. The baseline 25(OH)D level was significantly lower in nonresponders (14.8 ± 6.4 vs. 19.3 ± 7.6 ng/mL, P = 0.005). Vitamin D deficiency at baseline was associated with an increased risk of incomplete response independent of advanced stages (OR = 3.93, 95% CI = 1.02–15.19, P = 0.047). Similar results were obtained when biochemical response was evaluated by Barcelona criteria. Furthermore, 25(OH)D levels were lower in patients who subsequently suffered death or liver transplantation (12.1 ± 4.6 vs. 18.4 ± 7.6 ng/mL, P = 0.023).
Conclusions
25(OH)D level is associated with biochemical and histological features in PBC. Pre‐treatment vitamin D status is independently related to subsequent response to UDCA. Our results suggest that vitamin D status may have important clinical significance in PBC.
Full text
Available for:
BFBNIB, DOBA, FZAB, GIS, IJS, IZUM, KILJ, NLZOH, NUK, OILJ, PILJ, PNG, SAZU, SBCE, SBMB, SIK, UILJ, UKNU, UL, UM, UPUK
The cross section of the process e+e−→K+K− is measured at a number of center-of-mass energies s from 2.00 to 3.08 GeV with the BESIII detector at the Beijing Electron Positron Collider (BEPCII). The ...results provide the best precision achieved so far. A resonant structure around 2.2 GeV is observed in the cross section line shape. A Breit-Wigner fit yields a mass of M=2239.2±7.1±11.3 MeV/c2 and a width of Γ=139.8±12.3±20.6 MeV, where the first uncertainties are statistical and the second ones are systematic. In addition, the timelike electromagnetic form factor of the kaon is determined at the individual center-of-mass energy points.
Full text
Available for:
CMK, CTK, FMFMET, IJS, NUK, PNG, UM
Magnetic holes (MHs), with a scale much greater than ρi (proton gyroradius), have been widely reported in various regions of space plasmas. On the other hand, kinetic‐size magnetic holes (KSMHs), ...previously called small‐size magnetic holes, with a scale of the order of magnitude of or less than ρi have only been reported in the Earth's magnetospheric plasma sheet. In this study, we report such KSMHs in the magnetosheath whereby we use measurements from the Magnetospheric Multiscale mission, which provides three‐dimensional (3‐D) particle distribution measurements with a resolution much higher than previous missions. The MHs have been observed in a scale of 10–20 ρe (electron gyroradii) and lasted 0.1–0.3 s. Distinctive electron dynamics features are observed, while no substantial deviations in ion data are seen. It is found that at the 90° pitch angle, the flux of electrons with energy 34–66 eV decreased, while for electrons of energy 109–1024 eV increased inside the MHs. We also find the electron flow vortex perpendicular to the magnetic field, a feature self‐consistent with the magnetic depression. Moreover, the calculated current density is mainly contributed by the electron diamagnetic drift, and the electron vortex flow is the diamagnetic drift flow. The electron magnetohydrodynamics soliton is considered as a possible generation mechanism for the KSMHs with the scale size of 10–20 ρe.
Key Points
Magnetosheath kinetic‐size magnetic holes are found with electron flow vortex caused by diamagnetic drift
At the 90° pitch angle, the 34–66 eV electron flux decreased while 109–1024 eV electron flux increased inside the MHs
Quasi‐2‐D EMHD soliton theory is applicable to the observations
Full text
Available for:
BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SBCE, SBMB, UL, UM, UPUK
We study the e^{+}e^{-}→γωJ/ψ process using 11.6 fb^{-1} e^{+}e^{-} annihilation data taken at center-of-mass energies from sqrts=4.008 GeV to 4.600 GeV with the BESIII detector at the BEPCII ...storage ring. The X(3872) resonance is observed for the first time in the ωJ/ψ system with a significance of more than 5σ. The relative decay ratio of X(3872)→ωJ/ψ and π^{+}π^{-}J/ψ is measured to be R=1.6_{-0.3}^{+0.4}±0.2, where the first uncertainty is statistical and the second systematic (the same hereafter). The sqrts-dependent cross section of e^{+}e^{-}→γX(3872) is also measured and investigated, and it can be described by a single Breit-Wigner resonance, referred to as the Y(4200), with a mass of 4200.6_{-13.3}^{+7.9}±3.0 MeV/c^{2} and a width of 115_{-26}^{+38}±12 MeV. In addition, to describe the ωJ/ψ mass distribution above 3.9 GeV/c^{2}, we need at least one additional Breit-Wigner resonance, labeled as X(3915), in the fit. The mass and width of the X(3915) are determined. The resonant parameters of the X(3915) agree with those of the Y(3940) in B→KωJ/ψ and of the X(3915) in γγ→ωJ/ψ observed by the Belle and BABAR experiments within errors.
Full text
Available for:
CMK, CTK, FMFMET, IJS, NUK, PNG, UL, UM
The independent control of two magnetic electrodes and spin-coherent transport in magnetic tunnel junctions are strictly required for tunneling magnetoresistance, while junctions with only one ...ferromagnetic electrode exhibit tunneling anisotropic magnetoresistance dependent on the anisotropic density of states with no room temperature performance so far. Here, we report an alternative approach to obtaining tunneling anisotropic magnetoresistance in α'-FeRh-based junctions driven by the magnetic phase transition of α'-FeRh and resultantly large variation of the density of states in the vicinity of MgO tunneling barrier, referred to as phase transition tunneling anisotropic magnetoresistance. The junctions with only one α'-FeRh magnetic electrode show a magnetoresistance ratio up to 20% at room temperature. Both the polarity and magnitude of the phase transition tunneling anisotropic magnetoresistance can be modulated by interfacial engineering at the α'-FeRh/MgO interface. Besides the fundamental significance, our finding might add a different dimension to magnetic random access memory and antiferromagnet spintronics.Tunneling anisotropic magnetoresistance is promising for next generation memory devices but limited by the low efficiency and functioning temperature. Here the authors achieved 20% tunneling anisotropic magnetoresistance at room temperature in magnetic tunnel junctions with one α'-FeRh magnetic electrode.
To evaluate the prognostic value of the hypoperfusion intensity ratio (HIR) on 90-day clinical outcome in acute ischaemic stroke (AIS) patients with late therapeutic window.
One hundred and ...sixty-eight consecutive AIS patients with anterior-circulation large-vessel occlusion who underwent endovascular thrombectomy during the late window were enrolled retrospectively. Clinical data, Alberta Stroke Program Early Computed Tomography Score (ASPECTS) based on unenhanced computed tomography (CT), and perfusion parameters included ischaemic core, hypoperfusion volume, mismatch volume between core and penumbra, and the HIR were assessed and compared between patients with or without favourable outcomes (defined as modified Rankin Scale score of 0–2). Statistical analysis included binary logistic regression and receiver operating characteristic (ROC) analyses.
A favourable outcome was achieved in 76 (45.2%) patients. In univariable analysis, age, National Institutes of Health Stroke Scale (NIHSS) score at admission, ASPECTS score, HIR, ischaemic core, and hypoperfusion volume were significantly associated with functional outcome (p<0.05). In multivariate analyses, age (OR 0.95; 95% CI 0.92–0.99), NIHSS score at admission (OR 0.89, 95% CI 0.84–0.96) and HIR (OR 0.018, 95% CI 0.003–0.113) remained as independent outcome predictors (p<0.01). The optimal threshold of HIR was 0.36 (sensitivity 70.7%, specificity 61.8%). The combination of age, NIHSS score at admission, and HIR yield good performance for outcome prediction with an area under the ROC curve of 0.815 (sensitivity 88.2%, specificity 64.1%), significantly higher than individual variable (p<0.05).
Low HIR was a predictor for favourable outcome in AIS patients with late therapeutic window. Integrating HIR with clinical variables improved the ability for outcome classification.
•HIR was an independent imaging predictor for clinical outcome in AIS patients.•Patients with a low HIR (<0.36) are likely to have a favorable outcome.•Combination of clinical parameters and HIR could improve outcome prediction.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
Mutations in the PLA2G6 gene at the PARK14 locus have been reported in complicated parkinsonism. To assess the prevalence of and phenotypes associated with PLA2G6 gene mutations, we screened PLA2G6 ...mutations in a cohort of patients with autosomal recessive early-onset parkinsonism (AREP).
We selected 12 families with AREP in which the Parkin, PINK1, DJ-1, ATP13A2, and FBXO7 gene mutations had been previously excluded. All patients came from the mainland of China. The entire PLA2G6 coding region and exon-intron boundaries were sequenced from genomic DNA templates. We then performed PET studies on individuals in the pedigree with a homozygous PLA2G6 mutation, and investigated the enzyme activity level of the mutation.
A homozygous missense mutation, c.G991T (p.D331Y), was identified in an autosomal recessive case. A younger sister of the p.D331Y-carrying patient was also homozygous for the mutation, but with no extrapyramidal symptoms. A PET study showed a substantial reduction in dopamine transporter (DAT) binding in the p.D331Y patient, and a slight reduction in DAT binding in his sister. In vitro, we experimentally demonstrate that the D331Y mutation caused an approximately 70%reduction in enzyme activity.
We have confirmed that the PLA2G6 gene allocated PARK14 locus and is associated with AREP.
PDF
